Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ContraFect Corp    CFRX

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

ContraFect : Appoints Lisa Ricciardi as Chief Operating Officer

share with twitter share with LinkedIn share with facebook
share via e-mail
10/06/2017 | 12:13pm CEST

(GlobeNewswire) - ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announces that it has expanded its senior management team with the appointment of Lisa Ricciardi as Chief Operating Officer, effective immediately. Ms. Ricciardi will continue to serve in her role as a director of ContraFect.

Lisa has a unique blend of commercial, business development and overall operational experience that will be extremely helpful to ContraFect as our internal pipeline programs advance towards commercialization and we continue to evaluate business development strategies to accelerate value creation," said Steven C. Gilman, Ph.D.,ContraFect`sChairman and CEO. "Lisa has been a valuablemember ofourBoard of Directors since she joinedinFebruary, and we look forward to having her contribute full-time to support the continued growth ofContraFect."

Ms. Ricciardi commented, "I believe ContraFect has one of the most compelling new technologies in development to address the problem of antibiotic resistance. I am pleased to join a management team which has extensive experience in the development and commercialization of new antibiotic treatments.

Ms. Ricciardi is a Life Sciences executive with deep business development and operational experience at leading pharmaceutical, payer, and molecular diagnostics firms. She has previously served as Senior Vice President, Global Corporate & Business Development at Foundation Medicine and Senior Vice President, US and International Business Development at Medco Health Solutions, Inc., and was also a Venture Partner at Essex Woodlands Health Ventures. Ms. Ricciardi also held several senior management positions at Pfizer. As a commercial executive at Pfizer, Lisa was responsible for launching three drugs and growing franchises in cardiovascular disease, arthritis/rheumatology, and anti-infectives. Most notably, Lisa ran the anti-infectives commercial franchise at Pfizer and oversaw the launch of both Zithromax and Trovan. As Senior Vice President in the Licensing and Development Division at Pfizer, she closed more than 25 transactions with multi-national firms and biotechnology companies.

Ms. Ricciardi currently serves on the board United Drug Healthcare Group, PLC, and was a prior board member Chimerix Inc. as well as Sepracor Inc., which was sold to Dainippon Sumitomo for $2.6 billion.

About ContraFect:

ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect`s initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (Methicillin-resistant Staph aureus) and influenza. The Companys lead lysin, CF-301, is currently being studied in a Phase 2 multicenter, multinational, randomized, controlled clinical trial in patients with Staph aureus bacteremia including endocarditis. ContraFect is also conducting research focused on the discovery of lysins to target Gram-negative bacteria.


This press release contains, and our officers and representatives may make from time to time, forward-looking statements within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as projects, may, will, could, would, should, believes, expects, anticipates, estimates, intends, plans, potential, promise or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding our ability to discover and develop protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, Ms. Ricciardis experience and her ability to support the continued growth of ContraFect, the management teams experience in the development and commercialization of new antibiotic treatments, our ability to address life threatening infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses, whether our initial product candidates can treat antibiotic-resistant infections such as MRSA and influenza, and our ability to discover lysins targeting Gram-negative bacteria. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFects current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFects control, including those detailed in ContraFect`s filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations ContactPaul BoniContraFect CorporationTel: 914-207-2300Email:[email protected]

(c) 2017 Palestine News & Information Agency (WAFA). All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Stocks mentioned in the article
ChangeLast1st jan.
CONTRAFECT CORP -1.61% 2.44 Delayed Quote.141.58%
PFIZER -0.80% 37.36 Delayed Quote.3.98%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on CONTRAFECT CORP
06/14ContraFect to Present at JMP Securities Life Sciences Conference
06/02GLANCY PRONGAY & MURRAY LLP : Continues Investigation on Behalf of ContraFect Co..
05/31CONTRAFECT : to Present New Data on CF-301 (exebacase) and Lysins Targeting Gram..
05/30CONTRAFECT CORP : Change in Directors or Principal Officers, Financial Statement..
05/30ContraFect to Present New Data on CF-301 (exebacase) and Lysins Targeting Gra..
05/10CONTRAFECT CORP : Results of Operations and Financial Condition, Financial State..
05/10CONTRAFECT : 1Q Earnings Snapshot
05/10ContraFect Announces First Quarter 2018 Financial Results
05/09CONTRAFECT CORP : Submission of Matters to a Vote of Security Holders (form 8-K)
More news
News from SeekingAlpha
06/28ContraFect +8.3% as Janney starts at Buy 
06/28HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (06/28/2018) 
06/25Midday Gainers / Losers (06/25/2018) 
06/18CONTRAFECT : A Buy For Their Next Generation Anti-Infection Proteins 
06/15Midday Gainers / Losers (06/15/2018) 
Financials ($)
Sales 2018 -
EBIT 2018 -29,7 M
Net income 2018 -41,6 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 0
Capi. / Sales 2019 0
Capitalization 183 M
Duration : Period :
ContraFect Corp Technical Analysis Chart | CFRX | US2123261024 | 4-Traders
Income Statement Evolution
Mean consensus BUY
Number of Analysts 5
Average target price 3,56 $
Spread / Average Target 46%
EPS Revisions
Steven C. Gilman Executive Chairman, President & CEO
Michael Messinger Principal Financial Officer & Senior VP-Finance
Cara Cassino Chief Medical Officer & EVP-Research & Development
Sol J. Barer Lead Independent Director
Cary William Sucoff Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.--.--%32 830
LONZA GROUP8.17%21 400